

Has the survival of the graft improved after renal transplantation in the era of modern immunosuppression?

Francesc Moreso¹, Domingo Hernández²

¹ Servicio de Nefrología. Hospital Universitari Vall d'Hebron. Barcelona (Spain)

² Servicio de Nefrología. Hospital Regional Universitario Carlos Haya. Málaga (Spain)

Nefrología 2013;33(1):14-26

doi:10.3265/Nefrologia.pre2012.Oct.11739

ABSTRACT

The introduction of new immunosuppressant drugs in recent years has allowed for a reduction in the acute rejection rate along with highly significant improvements in short-term renal transplantation results. Nonetheless, this improvement has not translated into such significant changes in the long-term results. In this way, late graft failure continues to be the frequent cause of readmission onto dialysis programmes and re-entry onto the waiting list. Multiple insults of immune and non-immune origin act together and lead to chronic graft dysfunction. The characteristics of the transplanted organ are a greater determinant of graft survival and although various algorithms have been designed as a way of understanding the risk of the transplant organ and thus assign the most adequate receptor, its clinical application still only occurs in exceptional circumstances. Meanwhile, characterising, for each patient, the immune factors (clinical and subclinical rejection, reactivation of dormant viral infections, adherence to treatment) and non-immune factors (hypertension, diabetes, anaemia, dyslipidaemia) that contribute to chronic graft dysfunction could allow us to intervene more effectively as a way of delaying the progress of such process. Therefore, identifying the causes of graft failure and its risk factors, applying predictive models and intervening in causal factors could constitute some of the strategies for improving renal transplantation results in terms of survival. This review analyses some of the evidences conditioning graft failure as well as related therapeutic and prognostic aspects: 1) magnitude of the problem and causes of graft failure; 2) identification of graft failure risk factors; 3) therapeutic strategies for reducing graft failure, and; 4) graft failure prediction.

Keywords: Renal transplantation. Graft survival. Immunosuppression. Acute rejection. Chronic rejection.

Correspondence: Francesc Moreso

Servicio de Nefrología.

Hospital Universitari Vall d'Hebron.

Passeig Vall d'Hebron, 119-129. 08035 Barcelona. (Spain)

fjmoreso@vhebron.net

¿Ha mejorado la supervivencia del injerto tras el trasplante renal en la era de la moderna inmunosupresión?


RESUMEN


Durante los últimos años, la introducción de nuevos fármacos inmunosupresores ha permitido reducir la tasa de rechazo agudo y mejorar de forma muy significativa los resultados del trasplante renal a corto plazo. Sin embargo, esta mejoría no se ha traducido en cambios tan significativos en los resultados a largo plazo, de tal forma que el fracaso tardío del injerto sigue siendo una causa frecuente de reingreso en programas de diálisis y de reentrada en la lista de espera. Múltiples agresiones de origen inmune y no inmune actúan de forma conjunta y conducen a la disfunción crónica del injerto. Las características del órgano implantado son un determinante mayor de la supervivencia del injerto y, aunque se han diseñado diversos algoritmos para conocer el riesgo del órgano a trasplantar y poderlo asignar al receptor más adecuado, su aplicación en la clínica es todavía excepcional. Por otra parte, caracterizar en cada paciente los factores inmunes (rechazo clínico y subclínico, reactivación de infecciones virales latentes, adherencia al tratamiento) y no inmunes (hipertensión, diabetes, anemia, dislipemia) que contribuyen a la disfunción crónica del injerto puede permitirnos intervenir de forma eficaz para retrasar la progresión de este proceso. Por lo tanto, identificar las causas de fracaso del injerto y sus factores de riesgo, aplicar modelos predictivos e intervenir sobre los factores causales pueden ser algunas de las estrategias para mejorar los resultados de trasplante renal en términos de supervivencia. En esta revisión se analizan algunas de las evidencias que condicionan el fracaso del injerto, así como los aspectos terapéuticos y pronósticos relacionados con este: 1) Magnitud del problema y causas de fracaso del injerto; 2) Identificación de los factores de riesgo de fracaso del injerto; 3) Estrategias terapéuticas para disminuir el fracaso del injerto; y 4) Predicción del fracaso del injerto.

Palabras clave: Trasplante renal. Supervivencia del injerto. Inmunosupresión. Rechazo agudo. Rechazo crónico.

INTRODUCTION

Kidney transplantation (TX) constitutes the treatment of choice for patients with End-stage renal disease (ESRD), since it is associated with a greater rate of patient survival, improved





quality of life, and lower economic cost than renal replacement therapy with dialysis.¹ In the last few decades, this type of treatment has become progressively more accessible to a greater number of patients, such that in Spain, approximately half of all patients with ESRD have functioning TX.² Current registries from several countries have confirmed the progressive improvement in short-term TX results. Currently, the incidence of acute rejection is <15%, and graft survival at one year is >90%. In contrast, the evaluation of long-term results has been difficult to interpret, since contradictory data have been reported.^{3, 4} The rate of graft loss following the first year post-transplant is situated between 3% and 6% per year, and return to dialysis following graft failure is one of the most common causes of starting dialysis programmes and re-entering the organ wait list.⁵

In recent years, we have seen changes in the demographic and comorbidity characteristics of TX donors and recipients that undoubtedly have influenced these results.⁶ On the other hand, new immunosuppressant drugs have been introduced into the market that have allowed for reducing the rates of episodes of acute rejection. In addition, patients with TX have increasingly been prescribed medications with potentially protective effects for the heart and kidneys (anti-hypertensives, statins, and anti-platelets), which could modify progression towards renal failure.

In order to evaluate late graft failure, we need adequate information regarding the causes of graft failure, which requires histological analyses of the allograft, once vascular and urinary tract issues are ruled out. The international classification system proposed by the Banff group⁷ has been modified several times since its introduction in 1991 to incorporate newly acquired knowledge.⁸⁻¹¹ During the 1990s, chronic transplant nephropathy (CTN) became the primary cause of graft failure,^{12, 13} but the low specificity of this diagnosis has limited the analysis of causes of graft failure. In addition, during recent years, more sensitive techniques have become available for detecting HLA antibodies, which have contributed to characterising the role of antibody-mediated rejection.¹⁴

As such, extending graft survival following TX has become a clinical priority. With this in mind, an understanding of the causes of graft failure, identification of the risk factors that influence this entity, application of predictive models, and interventions for treating its causal factors could be beneficial strategies for optimising TX results.

In our review, we consider the aetiopathogenic evidence available for graft failure, and the therapeutic and prognostic aspects of this phenomenon under the following sub-headings of clinical relevance: 1) magnitude of the issue and causes of graft failure; 2) identification of risk factors; 3) therapeutic strategies for minimising graft failure and 4) predicting graft survival.


1. MAGNITUDE OF THE ISSUE AND CAUSES OF GRAFT FAILURE


Currently, no Spanish registry of TX is available that provides precise information regarding the rates and causes of graft loss. As such, we will extract our information from international registries, autonomic registries, and one Spanish study,^{6, 15} which evaluated cohorts of patients receiving transplants in 1990, 1994, 1998 and 2002, a total of almost 5000 individuals who reached one year post-transplant with a functioning graft (Spanish Group for the Study of Chronic Transplant Nephropathy [GEENCT]).¹⁶ Until only recently, live-donor transplantation was a rarity in Spain, and so national long-term results are not available.

New immunosuppressant agents were introduced into clinical practice during the late 1990s and start of the new millennium, accompanied by decreases in acute rejection rates from 40%-50% to 10%-15%. In addition, graft failure due to acute rejection has become quite an uncommon cause of graft loss in patients with a low immunological risk (1%-2%).^{17, 18} Currently, in the first year following TX, the primary cause of graft failure is related to complications of the surgical procedure, especially in the form of vascular thrombosis (2%-5%).^{17, 18} The use of non-heart beating donors and expanded criteria donors has been associated with a significant percentage of cases of primary graft failure, which can reach 20% in cases of non-heart beating donations.¹⁹

In order to evaluate the impact of new immunosuppression regimens on transplant results after 1 year, we must compare cohorts of patients who received transplants during each individual era of immunosuppression therapy. Data from an Australian registry,²⁰ which compared cohorts of patients who received transplants between 1993 and 2004, demonstrated a decrease in acute rejection rates from 40% to 23%, which was accompanied by an improvement in graft survival from cadaveric donors after 1 year (85% vs 90.2%) and after 5 years (69.9% vs 76.7%). The results for European patients provided by the Collaborative Transplant Study (CTS)²¹ suggest a very significant increase in mean graft survival (12.5 years for 1988-1990 vs 21.8 years for 2003-2005). In contrast, the improvements in long-term transplant results in the United States have been more modest, with increases in mean graft survival from 6.6 years in 1989 to 8.8 years in 2005 for cadaveric donations. At any rate, the data from this registry reveal a decrease in annual graft loss from 1989 to 2005 of 6%-8% to 4%-7%, during the first 10 years post-transplantation. In addition, if we exclude patient death with a functioning graft from the analysis, this rate improves from a 4%-6% rate of annual graft loss to 2%-4% for standard donors.²²

In Spain, data from the Catalan registry revealed that between 1984-1989 and 2002-2009, short-term and mid-term results have seen great improvement.⁵ Survival after one year





increased from 78.1% to 89.4%, while 5-year survival increased from 58.1% to 76.7%. This indicates that the annual rate of graft loss between the 2nd and 5th years has reduced from 4% to 2.5%. In contrast, the GEENCT¹⁵ results demonstrate that the decrease in acute rejection rates from 46% to 15.8% between 1990 and 2002 was accompanied by a non-significant increase in mean graft survival, after adjusting for patient death (15 years vs 19 years). Finally, in Spain, a single-hospital study involving more than 1400 cases demonstrated that mean graft survival increased significantly by almost 1 year between 1985-1995 and 1996-2005.²³

The results for graft survival must always be evaluated in the context of demographic changes in the donor and recipient populations. In order to overcome this limitation, the GEENCT performed a case-control study pairing the population of all 4 cohorts based on 6 donor and recipient variables.²⁴ This study showed that the decrease in acute rejection rates was correlated with a significant improvement in long-term results.


Finally, it appears that a substantial portion of the differences reported between countries is associated with the methodologies employed, such that a comparative study between GEENCT patients and patients from the American registry, in which the same methodology was used and after adjusting for confounding factors and patient death, demonstrated a similar 10-year graft survival rate between the two countries (75.6% vs 76%).²⁵

The evaluation of causes of late graft failure has undergone a significant change in recent years. The definition of CTN established by the Banff group in 1991 led to the dominance of this non-specific entity as the leading cause of late graft failure for many years.¹³ The presence of interstitial fibrosis and tubular atrophy (IF/TA), which defines CTN, is a very common finding in several analyses of surveillance biopsies, and is found in more than 60% of all grafts 1 year after transplantation.^{12, 26} Several studies have confirmed that the presence of isolated IF/TA in stable grafts is not associated with a worse prognosis for the transplant,^{27, 28} and that other types of lesions must be identified that might contribute to chronic dysfunction. In Figure 1, different patterns are suggested for explaining the appearance of chronic kidney allograft dysfunction. During the first few months following transplantation, we observe a loss in renal function associated with ischaemia/reperfusion damage and episodes of cellular immunological dysfunction or antibody-mediated dysfunction. Afterwards, many grafts maintain stable renal function for several years, with progressive decreases in renal function only if some triggering event occurs (black line in Figure 1). Recent studies suggest that this phenomenon is often observed in correlation with the appearance of *de novo* donor-specific antibodies (DSA) in the context of inadequate immunosuppression.^{29,30} The histological pattern observed is that of chronic humoral rejection,¹⁰ characterised by the

presence of microcirculation inflammation in the graft and transplant glomerulopathy (with or without C4d deposits). Non-adherence to immunosuppressant treatments and the use of minimal immunosuppression therapy (due to associated pathologies or other reasons) appear to be the primary causes of this phenomenon. In addition, insufficient treatment may be associated with episodes of late acute rejection (cellular, humoral, or mixed), producing inadequate response to treatment. Other mechanisms may less commonly be associated with this phenotype (recurring or *de novo* glomerulonephritis or severe concomitant diseases).

A second phenotype of chronic allograft dysfunction that may arise is when the damage produced during the first few months after transplantation leads to a progressive and slow loss in renal function over the following years (dark grey line in Figure 1). Analyses of surveillance biopsies show that persistent acute cellular rejection may affect 5%-10% of all grafts, and could contribute to a progressive loss in functioning nephrons, with progressive IT/TA and glomerulosclerosis.³¹ In addition, studies of surveillance biopsies taken from patients with pre-formed DSA have revealed a very high percentage of cases involving persistent microcirculation inflammation associated with the appearance of antibody-mediated rejection³² and accelerated graft arteriosclerosis.³³ Apart from the persistent immunological damage (mediated by T-cells and/or antibodies), other non-immunological lesions (recurrent or *de novo* kidney diseases, repeated bacterial and viral infections, and obstructive uropathy) could contribute to the appearance of this second phenotype. For many years, debate has persisted regarding the role of nephrotoxicity from calcineurin inhibitors in the development of chronic allograft dysfunction, since some of the lesions associated with this type of treatment can also be associated with insufficient immunosuppression therapy.^{34,38} Although there is a general consensus that nephrotoxicity contributes to the progression of chronic kidney disease (CKD), recent studies suggest that, alone, this isolated lesion is only rarely the cause of chronic allograft dysfunction.^{17,30} Finally, the characteristics of the allograft can also affect prognosis very significantly.^{39,40} In this manner, recipients of organs from expanded-criteria donors (light grey line in Figure 1) reach significantly lower levels of renal function during the first few months following transplantation. In this context, mechanisms of accelerated senescence⁴² and/or hyperfiltration⁴¹ can mediate the progression of renal failure without any new event directly participating in the development of new lesions to the allograft.

Table 1 summarises two recent studies that have reviewed the contribution of the aforementioned causes to graft failure. The study design and terminology employed in each of these are responsible for a large portion of the differences observed. Finally, it is possible that the combination of several factors is fundamentally responsible for chronic allograft dysfunction.







Figure 1. Different patterns of evolution of kidney function in kidney transplants with chronic allograft dysfunction.


ECD: expanded-criteria donor; SCD: standard criteria donor; GFR: glomerular filtration rate; GN: glomerulonephritis; I/R: ischaemia/reperfusion; CNI: calcineurin inhibitors; ACR: acute cellular rejection; AMAR: antibody-mediated acute rejection; AMCR: antibody-mediated chronic rejection.


2. IDENTIFICATION OF RISK FACTORS FOR GRAFT FAILURE

The analysis of risk factors for short and long-term graft failure has recently been revised.^{43,44} In order to carry out an adequate analysis, we must separate the respective variables present at the moment of TX from those that appear afterwards, since on many occasions, these reflect the result of an interaction between the clinical and immunological characteristics of the donor and recipient. Table 2 displays the pre- and post-transplant variables that are related to kidney graft survival, including immunological and non-immunological factors. The demographic characteristics of both donors and recipients and their associated comorbidities stand out among the non-immunological factors. Pre-transplant immunological factors are particularly important in determining the evolution of the kidney graft. Pretransplant sensitisation due to transfusions, pregnancy, or previous transplantations are all consistently associated with decreased graft survival. In the era of modern immunosuppression, the impact of HLA compatibility on graft survival is lower, but in studies from a registry with a large number of patients, the number of HLA compatibilities continues to maintain its correlation with graft survival.⁴⁵

The impact of post-transplant variables on graft survival varies according to study. The various comorbidities that can affect transplant recipients (arterial hypertension, diabetes, viral infections, and recurrence of underlying disease) are associated with variables inherent to the patient (such as age and obesity), but are also related to the type of immunosuppression received. Immunosuppression regimens involving maintenance therapy with tacrolimus, mycophenolate mofetil, and corticosteroids are associated with a higher prevalence of diabetes, arterial hypertension, and viral infections, whereas regimens based on mTOR (mammalian target of rapamycin) inhibitors are associated with a higher prevalence of dyslipidaemia, but a lower prevalence of arterial hypertension and viral infections. Several clinical trials and meta-analyses have examined the risks and benefits of removing corticosteroid treatment,⁴⁶ but we must not forget that some types of glomerulonephritis can recur more frequently after their removal,⁴⁷ and the evolution of DSA under this strategy remains unclear.

Acute rejection can have a negative impact of the first order on patient evolution. Recent studies have shown that episodes of acute cellular rejection that react to corticosteroid therapy with complete recovery of renal function have no impact on survival. However, episodes of severe acute rejection,



**Table 1.** Causes of kidney graft failure in 2 case series

	El Zoghby et al.¹⁷	Sellares et al.³⁰
Evaluated Group	Transplants 1996-2006	Biopsies due to dysfunction
Centre	Clínica Mayo Rochester	Edmonton
Number of cases	1317	315
Number of losses	192 (14.58%)	60 (19.04%)
Never functioning kidney	39 (2.96%)	Non applicable
	Vascular thrombosis n=33	
Acute cellular/humoral rejection	14 / 4 (1.37%) < 1 year n=6; >1 year n=12	0
Recurrent/ De novo Glomerulonephritis	23 / 10 (2.50%)	10 (3.17%)
Transplant glomerulopathy / AMCR or mixed	23 (1.75%) / not evaluated	Not evaluated / 36 (11.43%)
IF/TA	47 (3.57%) Persistent rejection n=13 BK Polyomavirus n=11 Pyelonephritis n=7 Nephrotoxicity n=1 Others n=15	4 (1.27%) BK Polyomavirus
Others/ Non-classified	25 / 7 (2.43%)	6 / 4(3.17%)


Percentages between parentheses have been calculated over the total number of cases evaluated.


IF/TA: interstitial fibrosis/tubular atrophy; AMCR: antibody-mediated chronic rejection.

Table 2. Risk factors associated with graft failure

PRE-TRANSPLANT FACTORS		
Donor factors	Recipient factors	Immunological factors
Cadaveric donor	Female sex	Prior sensitisation
Non-heart beating donor	Disproportionate size	Prior transplant
Age	Obesity	HLA compatibility
Female sex	Comorbidity	
Comorbidity	Tobacco use	
Cold ischemia time	Genetic polymorphisms	
POST-TRANSPLANT FACTORS		
Recipient comorbidity	Morpho-functional factors	Immunological factors
Arterial hypertension	Acute tubular necrosis	Immunosuppressant treatment
Post-transplant diabetes mellitus	Renal function	Acute rejection (severe, corticosteroid-resistant, antibody-mediated, late)
Anaemia	Proteinuria	Sub-clinical rejection (cellular, antibody-mediated)
Recurrence of underlying disease	Resistance index	Non-adherence to treatment
Infections (CMV, BK virus, pyelonephritis)	Surveillance biopsies (interstitial fibrosis/tubular atrophy, allograft vasculopathy, inflammation in fibrotic areas)	
Obstructive uropathy		

CMV: cytomegalovirus.





rejection with a vascular component, and acute antibody-mediated rejection are associated with decreased graft survival.⁴⁸ In addition, episodes of late acute rejection are associated with insufficient immunosuppression therapy, and are characterised by inadequate response to treatment.⁴⁸ Other studies with surveillance biopsies have shown that sub-clinical episodes of cellular or antibody-mediated rejection are associated with a worse prognosis for graft survival.³¹⁻³³ Regardless, in the modern era of immunosuppression, the prevalence of sub-clinical rejection is very low (less than 5%) in patients with low immunological risk.^{49, 50} Finally, non-adherence to immunosuppressant regimens has been associated both with the appearance of episodes of acute late rejection and with DSA and chronic humoral rejection.³⁰ Currently, the only available tool for evaluating adherence to treatment is monitoring blood levels for immunosuppressant drugs, although several studies have demonstrated that non-adherence is correlated with several variables related to the recipient (adolescents, low socio-economic standing, etc.).

Acute post-TX tubular necrosis is associated both with a greater risk of acute rejection and with a greater risk for chronic dysfunction, regardless of the presence of rejection.⁵¹ Renal function parameters at 3-6 months post-TX, the presence of proteinuria (even at low levels of 0.15-1g/day), and progression of renal function/proteinuria from months 3 to 12 are also associated with late graft failure.^{15,52} Other variables that have been less commonly used to monitor graft health, such as resistive index obtained by Doppler ultrasound^{53,54} and findings from surveillance biopsies,²⁶ have also been associated with graft failure.

3. THERAPEUTIC STRATEGIES FOR MINIMISING GRAFT FAILURE


Therapeutic strategies for reducing the rate of graft loss must act upon the aforementioned risk factors. Obviously, we cannot control the demographic variables and comorbidities of recipients and donors, but these variables must be taken into account when assigning recipients for each donated organ in order to maximise the viability of transplant results. One of the simplest proposals is the use of organs from elderly donors for elderly recipients,^{55, 56} although some studies have shown that the benefits obtained by this method of assignment are scarce, and limit access to transplants for younger recipients.⁵⁷⁻⁵⁹ It has also been proposed that organs obtained from expanded-criteria donors be used for non-sensitised recipients of more than 60 years of age (or more than 40 years for diabetics), or for recipients with severe issues with their vascular access.⁶⁰ Alternatively, various algorithms have been developed with the goal of optimising the results of a given transplant by taking into account the principles of equality (equal opportunity for all recipients on the wait list), efficiency


(minimising the rate of graft loss due to the death of patients with a functioning graft), and usefulness (maximising the number of patients with a functioning graft in order to minimise the rate of re-entry onto the wait list). The necessary algorithms for these systems of organ assignment are complex and require the collaboration of statisticians and mathematicians who take into account the characteristics of the population and the impact that these variables have on graft survival. Figure 2 displays the algorithm proposed by Baskin-Bey and Nyberg,^{61,62} taking into account risk scores for the donor and recipient and following the principle that the number of donors and recipients at each risk level is not homogeneous, and as such, the number of patients at each risk range for recipients must be adjusted to the availability of organs based on donor score.

Ischaemia-reperfusion damage is one of the limiting factors for renal function in the immediate post-transplant period, which can lead to acute tubular necrosis. The two most useful strategies for attenuating this damage, especially in high-risk grafts (expanded-criteria donors and non-heart beating donors), is to minimise cold ischaemic time⁶³ and to maintain the graft on a pulsatile perfusion machine rather than in cold storage.⁶⁴

The immunosuppression regimen used can play a key role in determining graft survival. Currently, the majority of centres use a combination of a calcineurin inhibitor (tacrolimus or cyclosporine), an anti-proliferative agent (mycophenolate mofetil or azathioprine), and corticosteroids. Treatment with tacrolimus has been associated with a lower rate of clinical and sub-clinical acute rejection, better renal function, and improved graft survival than treatment with cyclosporine or sirolimus in clinical trials and meta-analysis.^{65, 66} In contrast, the benefits of mycophenolate mofetil in short and mid-term results⁶⁷ have not always been consistently confirmed.^{68, 69} Regardless, the choice of what type of immunosuppression to administer must be balanced with the toxicities inherent to each medication. Tacrolimus is associated with a greater prevalence of post-transplant diabetes and neurotoxicity,⁶⁵ whereas mTOR inhibitors produce a lower degree of renal toxicity, lower prevalence of viral infections, and lower prevalence of cancer. Studies have shown that modifications to immunosuppression regimens over the course of patient follow-up must be accompanied by monitoring of the immune response through measuring anti-HLA antibodies.¹⁵

Arterial hypertension affects more than 75% of all recipients, and is correlated with renal function and treatment with a variety of immunosuppressants.⁷⁰





short reviews

Treatment with calcium channel blockers counteracts the vasoconstriction induced by calcineurin inhibitors and is associated with improved renal function and graft survival.⁷¹ In contrast, the use of renin-angiotensin-aldosterone system inhibitors, which can reduce graft fibrosis and proteinuria and improve graft survival, has provided contradictory results.⁷²⁻⁷⁴ Although their use has been associated with reduced glomerular filtration rates and more severe anaemia,⁷⁵ the GEENCT analysis suggests that their use could also be associated with reduced graft loss when started early.⁷⁶ Finally, the necessary treatment regimen, including diuretics, must be administered to maintain blood pressure below 130/80mm Hg, keeping in mind that many patients have a circadian pattern to their blood pressure values (non-dipper or reverse dipper), which has also been related to graft survival.⁷⁷ No clinical

trials have evaluated whether chronotherapy can modify patient or graft survival.


Pre- and post-transplant diabetes has been associated with graft survival, producing greater rates of mortality and graft failure.⁷⁸ As such, proper control of glycaemia through diet, lifestyle habits, and the use of oral anti-diabetics and/or insulin can increase graft survival. Studies have suggested that the changes produced by diabetic nephropathy appear earlier in transplanted kidneys than in native kidneys.⁷⁹


Dyslipidaemia affects more than 50% of kidney recipients, and its treatment can reduce the rate of cardiovascular events. However, although one clinical trial demonstrated a slower progression of graft vasculopathies after 6 months,⁸⁰ the use

Donor score (DDS)			Recipient score (RRS)							
Age	< 30 a.	0	Clinical variables				Age range			
	30-39 a.	5	D.M.	IHD	Dialysis <1 a	Dialysis >1a	1	2	3	4
	40-49 a.	10	0	0	0	0	10-57	58-73	74-84	>84
	50-59 a.	15	0	0	0	1	18-53	54-70	71-80	>80
	60-69 a.	20	0	0	1	0	18-47	48-64	65-74	>75
	> 60 a.	25	0	1	0	0	18-50	51-67	68-77	>77
AHT	no	0	0	0	0	1	18-46	47-63	64-74	>75
	Yes (?)	1	0	0	1	0	18-41	42-58	50-69	>70
	0-5 a.	2	1	0	0	0	18-34	35-70	71-90	-
	6-10 a.	3	1	0	0	0	18-27	28-62	63-85	>85
Final CrCl	> 100	0	1	0	1	0	-	18-51	52-73	>74
	75-99	2	1	1	0	0	18-20	21-55	56-78	>79
	50-74	3	1	0	0	1	18-48	49-71	>72	-
	<50	4	1	0	1	0	18-36	37-60	>61	-
HLA mm	0	0	1	0	0	0	-	-	-	-
	1-2	1	1	0	1	0	-	-	-	-
	3-4	2	1	0	1	0	-	-	-	-
	5-6	3	1	1	0	0	-	-	-	-
Cause of death	no CVA	0	1	1	0	0	-	-	-	-
	CVA	3	1	0	0	1	-	-	-	-
Final score		0-39								

Figure 2. Algorithm for calculating risk scores among donors and recipients.

Algorithm for calculating donor and recipient risk scores as proposed by Baskin-Bey et al.^{61, 62} The sum of points for each donor and recipient variable allows for calculating risk scores. It is proposed that kidneys be categorised based on risk (A=0-9 points; B=10-19 points; C=20-29 points; and D=30-39 points), and that recipients also be stratified based on risk. Recipient risk score is calculated using a formula that takes into account the variables indicated in the Table, as well as interactions between each variables (1<0-2.555; 2=2.556-3.308; 3=3.309-3.802; and 4>3.803). Kidneys are assigned based on both risk scores (A donors for class 1 recipients, B donors for class 2 recipients, C donors for class 3 recipients, and D donors for class 4 recipients). CVA: cerebrovascular accident; IHD: ischaemic heart disease; CrCl: creatinine clearance in ml/min; DM: diabetes mellitus; HLA mm: HLA mismatches; AHT: arterial hypertension.





of statins does not seem to modify graft survival based on results from clinical trials and registry analyses, including the data from the GEENCT.^{81,82}

Anaemia is a common complication in patients receiving kidney transplants (35%-40%) and has a substantial impact on patient and graft survival. Treatment with erythropoiesis-stimulating agents in patients with chronic allograft dysfunction reduces the requirement for transfusions and improves patient quality of life.⁸³ The target haemoglobin level for patients receiving kidney transplants with chronic dysfunction has yet to be established, and although it can be assumed to be the same as in individuals without transplants (10-12g/dl), a recent clinical trial suggests that normalised haemoglobin levels (13-15g/dl) are safe and are associated with a reduced progression of renal failure after 2 years (2.4ml/min/1.73m² in the normalisation group vs 5.9ml/min/1.73m² in the partial correction group).⁸⁴

4. PREDICTING GRAFT SURVIVAL

Chronic allograft dysfunction is characterised by a progressive deterioration in glomerular filtration rate (GFR) over time, which can be modelled in different ways. The exponential model has been widely used to estimate graft half-life, defined as the time elapsed until 50% of grafts have failed. Unfortunately, in the context of TX, this type of model tends to overestimate half-life for cohorts of patients with a short follow-up period.^{3, 4, 15}

In effect, using the GEENCT data, Seron et al.¹⁵ evaluated the goodness of fit for 5 models (exponential, Weibull, gamma, log-normal, and log-linear) to estimate graft half-life, concluding that the exponential model over-estimates graft half-life (between 1990 and 2002, an increase from 14 years to 52 years), whereas the other models had a similar goodness of fit and confirmed a non-significant increase in graft half-life between 3 and 4 years. Figure 3 displays an example of the log-linear distribution that provides the best fit.

In order to monitor loss in renal function, we can also measure the decrease in GFR over time. Using data from an American registry, Srinivas et al.⁸⁵ demonstrated that between 2003 and 2008, the evolution of renal function during the first 2 years post-transplant changed. During this period, GFR after 6 months increased from 53.1ml/min to 56.5ml/min, and the rate of loss of GFR between 6 and 12 months decreased from -1.18ml/min to +0.09ml/min, and from 12 to 24 months, the mean loss decreased from -4.29ml/min to 0ml/min. With this type of approximation, we can also model the progression of CKD, whether using linear models⁸⁶ or more complex models that take into account the fact that progression will be more accelerated at more advanced stages of CKD. In this context, Khalkhali⁸⁷ developed a model using a cohort of 214 patients with progressive CKD from the 1534 patients monitored during the period of 1997-2005. In this study, patients spent less time at each stage as CKD progressed (stage 1: 26.4 months; stage 2: 24.7 months; stage 3: 22.0 months; and stage 4: 18.5 months).






Figure 3. Log-normal survival function

Log-normal survival function that achieves the best fit with data from the study by Seron et al.¹⁵ Since the patients evaluated had all reached the first year post-transplant with a functioning graft, the probability of graft failure is not linear over time.





Other studies have analysed the risk factors associated with this progression or failure. In some models, only pre-transplant variables are taken into account,^{68, 86-91} whereas others also include post-transplant variables (Table 3).⁹² Several studies have compared the goodness of fit of various scores. The donor risk score defined by Schold et al.⁹⁰ provides one of the best fits with the development of stage 4 CKD one year after transplantation.⁹³ In other studies, histological variables have been included in addition to clinical variables. Anglicheau et al.⁴⁰ demonstrated the predictive value of a score composed of the percentage of sclerosed glomeruli in donor biopsies, donor hypertension, and serum creatinine >1.5mg/dl before organ extraction for predicting reaching a GFR<25ml/min (receiver operating statistic [ROC] area under the curve: 0.84).

Finally, although clinical (acute rejection, creatinine, and proteinuria) and histological data from surveillance biopsies have been associated with long-term graft survival, the long-term predictive capacity of these data is insufficient.^{26,94,95} For example, although the relative risk of graft failure increases by a magnitude of 2.2 for every mg/dl in serum creatinine

after one year, its predictive value in terms of ROC curves on graft failure after 7 years only provides an area under the curve of 0.62. The same occurs with CKD progression: measured as the inverse of creatinine, this parameter produces an area under the curve of 0.55. In fact, it has been proposed that neither acute rejection nor serum creatinine levels are appropriate measures of long-term graft survival.⁹⁶

Acknowledgements

This study was financed in part by the Spanish Ministry of Science and Innovation (Carlos III Health Institute, FIS PI10/0185 and PI10/01020), REDINREN RD12/0021/0015, the I Novartis-SET fund, and the Andalucía Health Department (PI-0499/2009).


Conflicts of interest


The authors declare that they have no conflicts of interest related to the contents of this article.

Table 3. Risk scores for graft loss

Name	Reference	Variables
ECD (<i>expanded criteria donor</i>)	Metzger RA et al. ⁸⁸	Donor age >60 years of age or >50 years with 2 of the following donor criteria: creatinine >1.5mg/dl, history of AHT, or death by ACV.
DDS (<i>donor deceased score</i>)	Nyberg SL et al. ⁸⁹	Donor variables: age, AHT (and duration), death by ACV, and creatine clearance. HLA mismatches
DRS (<i>donor risk score</i>)	Schold JD et al. ⁹⁰	Donor variables: age, race, history of AHT, and death by CVA. HLA mismatches. Cold ischaemia time. Donor/recipient CMV serology.
KDRI (<i>kidney donor risk index</i>)	Rao PS et al. ⁹¹	Donor variables: age, race, history of AHT, history of diabetes, serum creatinine, death by ACV, height, weight, non-heart beating donor, hepatitis C virus serology. B and DR mismatches. Cold ischaemia time. Dual or en bloc kidney transplant
<i>Delayed graft function nomogram</i>	Irish WD et al. ⁹²	Donor variables: age, AHT, non-heart beating donor, CVA, and anoxia. HLA mismatches. Cold ischaemia time. Recipient variables: race, age, diabetes, previous transplant, transfusion, dialysis, PR peak.
RRS (<i>recipient risk score</i>)	Baskin-Bey ES et al. ⁶²	Recipient variables: age, history of diabetes mellitus, ischaemic heart disease, and time on dialysis

CVA: cerebrovascular accident; AHT: arterial hypertension; PRA: panel reactive antibody percentage.







KEY CONCEPTS

1. Kidney allograft failure is an issue of the first order in the treatment of chronic kidney disease, since this is one of the more common causes for reintegration into dialysis programmes and the wait list.
2. The introduction of new immunosuppressant drugs has allowed for reducing acute rejection rates and improving long-term graft survival. At the same time, the combination of these drugs has contributed to reducing the rate of late graft failure.
3. An understanding of the causes and risk factors for allograft loss could facilitate early intervention on both immunological and non-immunological risk factors in order to prevent this graft failure.
4. Donor-related factors have a major influence on kidney graft survival. Algorithms designed to allocating organs to the appropriate recipient in order to optimise results are complex and difficult to implement in daily practice.
5. Continuous changes to the demographics and comorbidities of donors and recipients oblige us to continuously monitor changes in transplant results. At present, we do not have sufficiently precise models for determining long-term graft survival.


REFERENCES


1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N Engl J Med* 1999;341:1725-30.
2. Registro Español de Enfermos Renales. Informe 2006 de diálisis y trasplante renal en España. *Nefrología* 2009;29(6):525-33.
3. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. *N Engl J Med* 2000;342:605-12.
4. Meier-Kriesche HU, Schold JD, Kaplan D. Long-term renal allograft survival: have we made significant progress or it is time to rethink our analytic and therapeutic strategies? *Am J Transplant* 2004;4:1289-95.
5. Registre de malalts renals de Catalunya. Informe estadístic 2010. Barcelona: Servei Català de la Salut. Organització Catalana de Trasplantaments (OCATT); mayo 2012.
6. Serón D, Arias M, Campistol JM, Morales JM. Late renal allograft failure between 1990 and 1998 in Spain: a changing scenario. *Transplantation* 2003;76:1588-93.
7. Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. *Kidney Int* 1993;44:411-22.
8. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff working classification of renal allograft pathology. *Kidney Int* 1999;55:713-23.
9. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. *Am J Transplant* 2004;4(10):1562-6.
10. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). *Am J Transplant* 2007;7(3):518-26.
11. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. *Am J Transplant* 2008;8:753-60.
12. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003;349(24):2326-33.
13. Chapman J, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. *J Am Soc Nephrol* 2005;16:3015-26.
14. Ferrari-Lacraz S, Tiercy JM, Villard J. Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe? *Tissue Antigens* 2012;79:315-25.
15. Serón D, Moreso F, Arias M, Campistol JM, Curto J, Hernandez D, et al. Estimation of renal allograft half life: fact or fiction? *Nephrol Dial Transplant* 2011;26(9):3013-8. Erratum in: *Nephrol Dial Transplant* 2011;26(12):4153-4.
16. Hernández D, Sánchez Fructuoso A, Serón D, Arias M, Campistol JM, Morales JM, et al. Chronic transplant nephropathy. *Nefrología* 2006;26 Suppl 1:1-38.
17. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al. Identifying specific causes of kidney allograft loss. *Am J Transplant* 2009;9:527-35.
18. ANZDATA Registry Report 2004. Edited by McDonald S, Excell L. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia.
19. Hoogland ER, Snoeijs MG, Winkens B, Christaans MH, van Heurn LW. Kidney transplantation from donors after cardiac death: uncontrolled versus controlled donation. *Am J Transplant* 2011;11:1427-34.







20. Chang SH, Russ GR, Chadban SJ, Campbell SB, McDonald SP. Trends in kidney transplantation in Australia and New Zealand, 1993–2004. *Transplantation* 2007;84:611-8.
21. Collaborative Transplant Study. CTS Outcome Graphs. 2011; Graph K-14103E-0711. Available at: <http://www.ctstransplant.org/public/introduction.shtml>
22. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. *Am J Transplant* 2011;11:450.
23. Sola E, Gonzalez-Molina M, Cabello M, Burgos D, Ramos J, Gutierrez C, et al. Long-term improvement of deceased donor renal allograft survival since 1996: a single transplant center study. *Transplantation* 2010;89(6):714-20.
24. Moreso F, Alonso A, Gentil MA, González-Molina M, Capdevila L, Marcén R, et al. Improvement in late renal allograft survival between 1990 and 2002 in Spain: results from a multicentre case-control study. *Transpl Int* 2010;23(9):907-13.
25. Ojo AO, Morales JM, González-Molina M, Steffick DE, Luan FL, Merion RM, et al. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. *Nephrol Dial Transplant* 2012. doi:10.1093/ndt/gfs287 [Epub ahead of print].
26. Seron D, Moreso F. Protocol biopsies in renal transplantation: Prognostic value of structural monitoring. *Kidney Int* 2007;72:690-7.
27. Cosio FG, Grande JP, Wade H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. *Am J Transplant* 2005;5:2464-72.
28. Moreso F, Ibernón M, Gomà M, Carrera M, Fulladosa X, Hueso M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. *Am J Transplant* 2006;6(4):747-52.
29. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al. Evidence for antibody-mediated rejection injury as a major determinant of late kidney allograft failure. *Transplantation* 2010;90:68-74.
30. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. *Am J Transplant* 2012;12:388-99.
31. Nankivell BJ, Borrows RJ, Fung CLS, O'Connell PJ, Allen RDM, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. *Transplantation* 2004;78:242.
32. Loupy A, Souberbille-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. *Am J Transplant* 2009;9:2561-70.
33. Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, et al. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. *J Am Soc Nephrol* 2011;22:975-83.
34. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. *Transplantation* 2004;78:557-65.
35. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. *Clin J Am Soc Nephrol* 2009;4:481-508.
36. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. *Clin J Am Soc Nephrol* 2009;4:2029-34.
37. Krejci K, Tichy T, Hruby M, Horak P, Ciferska H, Horcicka V, et al. Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage. *Transpl Int* 2010;23(4):364-73.
38. Arias M, Seron D, Moreso F, Bestard O, Praga M. Chronic renal allograft damage: Existing challenges. *Transplantation* 2011;91(9 Suppl):S4-S25.
39. Cosio FG, Qiu W, Henry ML, Falkenhain ME, Elkhammas EA, Davies EA, et al. Factors related to the donor organ are major determinants of renal allograft function and survival. *Transplantation* 1996;62(11):1571-76.
40. Anglicheau D, Loupy A, Lefaucheur C, Pessione F, Létourneau I, Côté I, et al. A simple clinico-histopathological composite scoring system is highly predictive of graft outcomes in marginal donors. *Am J Transplant* 2008;8(11):2325-34.
41. Brenner BD, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. *N Engl J Med* 1982;309:652-9.
42. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. *J Am Soc Nephrol* 1999;10:167-81.
43. Nankivell BJ, Kuypers DRJ. Diagnosis and prevention of chronic kidney allograft loss. *Lancet* 2011;378:1428-37.
44. Ekberg H, Johansson ME. Challenges and considerations in diagnosing the kidney disease in deteriorating graft function. *Transpl Int* 2012;25(11):1119-28.
45. Opelz G, Döhler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. *Transplantation* 2007;84:137-43.
46. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. *Nephrol Dial Transplant* 2012;27:825-32.
47. Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. *Am J Transplant* 2011;11:1645-49.
48. McDonald S, Russ G, Campbell S, Chadban S. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. *Am J Transplant* 2007;7:1201-8.
49. Moreso F, Seron D, Carrera M, Gil-Vernet S, Cruzado JM, Hueso M, et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. *Transplantation* 2004;78(7):1064-8.
50. Rush D, Arlen D, Boucher A, Busque S, Cockfield SM, Girardin C, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. *Am J Transplant* 2007;7:2538-45.
51. Hernández D, Pérez G, Marrero D, Porrini E, Rufino M, González-Posada JM, et al. Early association of low-grade albuminuria and allograft dysfunction predicts renal transplant outcomes. *Transplantation* 2012;93:297-303.
52. Moreso F, Seron D, Gil-Vernet S, Riera L, Fulladosa X, Ramos R, et al. Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients. *Nephrol Dial Transplant* 1999;14:930-5.





53. Radermacher J, Mengel M, Ellis S, Stuh S, Hiss M, Schwarz A, et al. The renal arterial resistance index and renal allograft survival. *N Engl J Med* 2003;349:115-24.
54. Vallejos A, Alperovich G, Moreso F, Cañas C, de Lama ME, Gomà M, et al. Resistive index and chronic allograft nephropathy evaluated in protocol biopsies as predictors of graft outcome. *Nephrol Dial Transplant* 2005;20:2511-6.
55. Donnelly PK, Simpson AR, Milner AD, Nicholson ML, Horsburgh T, Veitch PS, et al. Age-matching improves the results of renal transplantation with older donors. *Nephrol Dial Transplant* 1990;5:808-11.
56. Waiser J, Schreiber M, Budde K, Fritsche L, Bohler T, Hauser I, et al. Age-matching in renal transplantation. *Nephrol Dial Transplant* 2000;15:696-700.
57. Kasiske BL, Snyder J. Matching older kidneys with older patients does not improve allograft survival. *J Am Soc Nephrol* 2002;13:1067-72.
58. Sola R, Guirado L, Lopez-Navidad A, Bonfill X, Diaz JM, Puig T, et al. Is it appropriate to implant kidneys from elderly donors in young recipients? *Transplantation* 2010;90:286-91.
59. Textor S, Nyberg S. Recipient and donor age in deceased donor transplantation: how should older donor kidneys be allocated? *Transplantation* 2010;90:246-7.
60. Danovitch GM, Cohen B, Smits JM. Waiting time or wasted time? The case for using time on dialysis to determine the waiting time in the allocation of cadaveric donors. *Am J Transplant* 2002;2:891-3.
61. Baskin-Bey ES, Kremers W, Nyberg SL. A recipient risk score for deceased donor renal allocation. *Am J Kidney Dis* 2007;49:284-93.
62. Baskin-Bey ES, Nyberg SL. Matching graft to recipient by predicted survival: can this be an acceptable strategy to improve utilization of deceased donor kidneys? *Transplant Rev (Orlando)* 2008;22:167-70.
63. Terasaki PI. Cold ischemia time—time to rethink the risk for kidneys. *Am J Transplant* 2011;11:2551-2.
64. Dikdan GS, Mora-Esteves C, Koneru B. Review of randomized clinical trials of donor management and organ preservation in deceased donors: opportunities and issues. *Transplantation* 2012;94:425-41.
65. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gürkan A, et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med* 2007;357:2562-75.
66. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. *Cochrane Database Syst Rev* 2005;(4):CD003961.
67. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. *Transplantation* 1997;63:39-47. Erratum in: *Transplantation* 1997;63:618.
68. Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: The MYSS follow-up, randomized, controlled clinical trial. *J Am Soc Nephrol* 2007;18:1973-85.
69. Clayton PA, McDonald SP, Chapman JR, Chadban SJ. Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial. *Transplantation* 2012;94:152-8.
70. Moreso F, Algre R, Bernis C, Beneyto I, Crespo JF, Delgado P, et al. Riesgo cardiovascular e hipertensión arterial postrasplante renal. *Nefrologia* 2009;29(Suppl 3):11-5.
71. Cross NB, Webster AC, Masson P, O'Connell PJ, Craig JC. Antihypertensive treatment for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. *Transplantation* 2009;88:7-18.
72. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, et al. Angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. *J Am Soc Nephrol* 2006;17:889-99.
73. Opelz G, Zeier M, Laux G, Morath C, Döhler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. *J Am Soc Nephrol* 2006;17:3257-62.
74. Hernández D, Muriel A, Abaira V, Pérez G, Porrini E, Marrero D, et al. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study. *Nephrol Dial Transplant* 2012;27:417-22.
75. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin-angiotensin system blockade in kidney transplantation: a systematic review of the evidence. *Am J Transplant* 2007;7:2350-60.
76. Hernández AA, Moreso F, Bayés B, Lauzurica R, Sanz-Guajardo D, Gómez-Huertas E, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain. *NDT Plus* 2010;(Suppl 2):ii21-ii25.
77. Ibernón M, Moreso F, Sarrias X, Sarrias M, Grinyó JM, Fernandez-Real JM, et al. Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation. *Nephrol Dial Transplant* 2012;27:2089-95.
78. Moreso F, Alegre R, Beneyto I, Bernis C, Calvo N, Crespo JF, et al. Consecuencias clínicas de la diabetes mellitus posterior al trasplante renal. *Nefrologia Supl Ext* 2010;1(2):15-20.
79. Bhalla V, Nast CC, Stollenwer N, Tran S, Barba L, Kamil ES, et al. Recurrent and de novo diabetic nephropathy in renal allografts. *Transplantation* 2003;75:66-71.
80. Seron D, Oppenheimer F, Pallardo LM, Lauzurica R, Errasti P, Gomez-Huertas E, et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled study. *Transplantation* 2008;86:82-7.
81. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet* 2003;361(9374):2024-31.
82. Moreso F, Calvo N, Pascual J, Anaya F, Jiménez C, Del Castillo D, et al. Early statin use is an independent predictor of long-term graft survival. *NDT Plus* 2010;(Suppl 2):ii26-ii31.





83. Moreso F, Alegre R, Ariceta G, Beneyto I, Bernis C, Calvo N, et al. Tratamiento de la anemia postrasplante renal. *Nefrologia Supl Ext* 2011;2(2):16-24.
84. Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. *J Am Soc Nephrol* 2012;23:360-8.
85. Srinivas TR, Flechner SM, Poggio ED, Askar M, Goldfarb DA, Navaneethan SD, et al. Glomerular filtration rate slopes have significantly improved among renal transplants in the United States. *Transplantation* 2010;90:1499-505.
86. Gill JS, Tonelli M, Mix CH, Pereira BJG. The change in allograft function among long-term kidney transplant recipients. *J Am Soc Nephrol* 2003;14:1636-42.
87. Khalkhali HR, Ghafari A. Prediction of long-term kidney failure in renal transplant with chronic dysfunction using stage-specific hazard rates. *Exp Clin Transplant* 2012;10:8-13.
88. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. *Am J Transplant* 2003;3(suppl 4):114.
89. Nyberg SL, Matas AJ, Kremers WK, Thostenson JD, Larson TS, Prieto M, et al. Improved scoring system to assess adult donors for cadaver renal transplantation. *Am J Transplant* 2003;3:715-21.
90. Schold JD, Kaplan B, Baliga RS, Meier-Kriesche HU. The broad spectrum of quality in deceased donor kidneys. *Am J Transplant* 2005;4(pt 1):757-65.
91. Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA, Merion RM, et al. A comprehensive risk quantification score for deceased donor kidneys: The Kidney Donor Risk Index. *Transplantation* 2009;88:231-6.
92. Irish WD, McCollum DA, Tesi RJ, Owen AB, Brennan DC, Bailly JE, et al. Nomogram for predicting the likelihood of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. *J Am Soc Nephrol* 2003;14:2967-74.
93. Moore J, Ramakrishna S, Tan K, Cockwell P, Eardley K, Little MA, et al. Identification of the optimal donor quality scoring system and measure of early renal function in kidney transplantation. *Transplantation* 2009;87:578-86.
94. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. *Am J Transplant* 2003;3:1560-5.
95. Schold JD, Kaplan B. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. *Am J Transplant* 2009;9:2067-74.
96. Schold JD, Kaplan B. The elephant in the room: failings of current clinical endpoints in kidney transplantation. *Am J Transplant* 2010;10:1163-6.

